Neutrophil-to-Lymphocyte Ratio and Extrahepatic Spread Predict Response and Survival in Unresectable Hepatocellular Carcinoma
{{output}}
Purpose: Identifying nonresponders to atezolizumab plus bevacizumab (AB) remains challenging in unresectable hepatocellular carcinoma (uHCC). We aimed to develop and externally validate a simple risk scoring system using baseline... ...
